Table 5.

Clinical trials using JAKi in Graft-versus-Host-Disease according to clinicaltrials.gov.

Disease subtype	Inhibitor	Target	Administration	Phase	Study number
Prophylaxis of GVHD	Itacitinib	JAK1	Oral	Phase I	NCT03320642
	Itacitinib	JAK1	Oral	Phase I	NCT03755414
aGVHD	Ruxolitinib	JAK1 JAK2	Oral	Phase II	NCT02396628
	Ruxolitinib	JAK1 JAK2	Oral	Phase III	NCT02913261
	Ruxolitinib	JAK1 JAK2	Oral	Phase II	NCT03702698
	Ruxolitinib	JAK1 JAK2	Oral	Phase II	NCT03491215
	Ruxolitinib	JAK1 JAK2	Oral	Phase II	NCT02953678
	Itacitinib	JAK1	Oral	Phase I	NCT03497273
	Itacitinib	JAK1	Oral	Phase I/II	NCT03721965
	Itacitinib	JAK1	Oral	Phase III	NCT03139604
	Itacitinib	JAK1	Oral	Phase II	NCT03846479
	Pacritinib	JAK2	Oral	Phase I	NCT02891603
aGVHD cGVHD	Ruxolitinb	JAK1 JAK2	Oral	Phase II	NCT02997280
cGVHD	Baricitinib	JAK1 JAK2	Oral	Phase I/II	NCT02759731
	Itacitinib	JAK1	Oral	Phase III	NCT03584516
	Ruxolitinib	JAK1 JAK2	Oral	Phase II	NCT03616184
	Ruxolitinib	JAK1 JAK2	Oral	n/a	NCT03147742
	Ruxolitinib	JAK1 JAK2	Oral	Phase III	NCT03112603
	Ruxolitinib	JAK1 JAK2	Topical	Phase II	NCT03395340

aGVHD, acute Graft-versus-Host-Disease; cGVHD, chronic graft-versus-host-diseases.